Business
Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced that it will hold an investor event at the Society of Immunotherapy for Cancer (SITC) Annual Meeting centered around the Company’s groundbreaking RedTail platform and its lead candidate, CLD-401. The presentation will take place at the SI
About this update from Calidi Biotherapeutics, Inc.
[{"type":"image","alt":"Calidi Biotherapeutics, Inc","displaySize":"","headline":null,"caption":"Calidi Biotherapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TVVsA9n31LT1YQqkVdlDAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1","width":300,"height":93}},"lazy":false},{"type":"text","content":"SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced that it will hold an investor event at the Society of Immunotherapy for Cancer (SITC) Annual Meeting centered around the Company’s groundbreaking RedTail platform and its lead candidate, CLD-401.","length":457,"tagName":"p"},{"type":"text","content":"The presentation will take place at the SITC Annual Meeting on Friday, November 7th from 8:30AM to 9:30AM in the National Harbor Room 15 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.","length":218,"tagName":"p"},{"type":"text","content":"The presentation will also be live streamed: (https://vimeo.com/event/5482626/8149f00207).","length":90,"tagName":"p"},{"type":"text","content":"Speakers at the event will include:","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Dmitriy Zamarin of the Icahn Genomics Institute and the Precision Immunology Institute at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Dr. Zamarin is a world renowned expert in virotherapy. Dr. Zamarin is a member of Calidi’s Scientific Advisory Board (SAB).","length":292,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Antonio F. Santidrian, Chief Scientific Officer of Calidi, responsible for leading all of the Company’s research and development initiatives.","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. John M. Wrangle, a thoracis medical oncologist at the Medical University of South Carolina (MUSC). Dr Wrangle is an expert on the clinical development of IL-15 superagonist. Dr. Wrangle is also...